Share on StockTwits

Acceleron Pharma (NASDAQ:XLRN) CEO John L. Knopf sold 17,500 shares of Acceleron Pharma stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $29.78, for a total value of $521,150.00. Following the completion of the transaction, the chief executive officer now directly owns 156,500 shares in the company, valued at approximately $4,660,570. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

XLRN has been the subject of a number of recent research reports. Analysts at Leerink Swann initiated coverage on shares of Acceleron Pharma in a research note on Thursday. They set an “outperform” rating and a $57.00 price target on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Acceleron Pharma in a research note on Wednesday. They set an “outperform” rating and a $47.00 price target on the stock. Four research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of $51.00.

Shares of Acceleron Pharma (NASDAQ:XLRN) traded down 0.50% during mid-day trading on Friday, hitting $29.81. The stock had a trading volume of 140,234 shares. Acceleron Pharma has a one year low of $16.78 and a one year high of $57.89. The stock’s 50-day moving average is $29.77 and its 200-day moving average is $36.09. The company’s market cap is $947.9 million.

Acceleron Pharma (NASDAQ:XLRN) last released its earnings data on Tuesday, August 12th. The company reported ($0.54) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.55) by $0.01. On average, analysts predict that Acceleron Pharma will post $-1.44 earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.